By Kyle Morris


ImmuPharma PLC said Friday that its U.S. partner Avion Pharmaceuticals LLC has agreed to continue its support of the clinical program of Lupuzor for lupus and that the companies will explore a distribution agreement to introduce certain Avion products into the European market.

The pharmaceutical company said the Lupuzor for Lupus clinical program is to be redesigned on key protocols in order to enhance the probability of success after a written response from the U.S. Food and Drug Administration.

The distribution agreement has the potential for product sales revenues for ImmuPharma, it said.

Shares in ImmuPharma at 0826 GMT were up 0.29 pence, or 8.9%, at 3.60 pence.


Write to Kyle Morris at kyle.morris@dowjones.com


(END) Dow Jones Newswires

11-11-22 0345ET